What should I bring to the appointment?
Bring a brief chronology of what you noticed, where it appeared, and what changed. Bring a current medicine list; relevant personal and family history; and any prior skin records or treatments. Add the practical and emotional questions you most want answered so they are not lost at the end of the visit. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this item matters
- Reasonably supported
Vitiligo assessment relies on history as well as examination. I read the guidance for what it keeps asking about: the distribution and change of patches, previous care, associated health history, and the effect on daily life. Those help the clinician understand both the medical picture and your goals.
Check before moving on
- Depends on you
You do not need a perfect timeline or a self-diagnosis. Old photographs may help establish what you observed, but differences in lighting and framing limit what they prove.
Questions for your clinician
Which parts of my history matter most to your assessment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What should I track before follow-up?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How should I record it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What does a collaborative first visit look like?
A collaborative clinician examines before concluding, explains the working diagnosis and uncertainty, asks what matters to you, and makes room for questions. You should be able to understand the purpose, tradeoffs, and follow-up logic of the options discussed. That holds even if the final decision is to wait or pursue no active treatment. Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this item matters
- Reasonably supported
The guidelines I read include quality of life and patient preferences in management. The AAD patient guidance I checked states there is no single best treatment for everyone. Those principles support shared decisions, rather than assuming that visible difference tells the clinician what outcome you want.
Check before moving on
- Depends on you
One rushed or complicated visit may not reveal the whole care relationship, and disagreement is not automatically poor care. The test I would use is whether questions are addressed honestly, and whether the next step is understandable and consistent with your goals.
Questions for your clinician
Can we agree on the goal before comparing options?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What is uncertain, and how would we revisit that uncertainty?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How can I contact the team if the plan or instructions are unclear?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How will the clinician decide whether this is vitiligo?
Start by asking what diagnosis the clinician thinks is most likely, what findings support it, and what else was considered. The clinician will usually take a history and examine the affected skin; a dermatologist may also use a Wood’s lamp or examine hair and other areas when relevant. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this item matters
- Reasonably supported
NIAMS, the AAD and the clinical guidelines I read put history and skin examination at the center of diagnosis. The clinician is trying to decide whether the change is vitiligo, whether the pattern can be classified, and whether the history suggests recent activity or another explanation.
Check before moving on
- Depends on you
Not every examination uses the same tools, and a single visit may leave genuine uncertainty. A careful clinician may suggest follow-up or a focused test rather than overstate what the first examination establishes.
Questions for your clinician
Do you think this is vitiligo? What supports that answer?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What other explanations did you consider, and why are they less likely?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Can you explain how you would describe the pattern and current activity?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Should I expect tests?
Tests may be discussed, but they are not a measure of how seriously the clinician takes you. Blood tests, an eye examination, or a skin biopsy may be considered when each would answer a question raised by your history or examination. Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this item matters
- Reasonably supported
NIAMS lists these as possible parts of evaluation, including testing for associated autoimmune disease and biopsy when examining skin tissue would help. The guidelines I checked also weigh relevant comorbidity and differential diagnosis in the work-up.
Check before moving on
- Depends on you
Your clinician chooses tests based on your symptoms, history, age, examination, and the question that needs answering.
Questions for your clinician
What question is this test intended to answer?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would a positive, negative, or unclear result change?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If we do not test now, what would make you reconsider?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
If it is vitiligo, do I need to choose a treatment today?
The conversation should begin with your goals and the clinician’s assessment. Pattern, apparent activity, body sites, age, overall health, prior care, access, and the effect on your life can all shape which options are worth discussing. You do not need to arrive having chosen one. Evidence Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this item matters
- Reasonably supported
Which treatment to pick is what patients ask about more than anything else, and there are enough options to freeze you. The clinical and patient guidance I read describes several treatment and non-treatment paths, and names no universally best choice. A useful discussion distinguishes what an option is intended to do, its burdens and material risks, the evidence behind it, and how progress would be reviewed.
Check before moving on
- Depends on you
No option guarantees repigmentation or control of change for an individual, and body sites can behave differently. Evidence from a study or guideline still needs clinical interpretation for you.
Questions for your clinician
Do I need to decide today?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What goal would each option address, and what would it not address?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What are my reasonable options if I do not want active treatment now?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What should I understand before I leave?
Before leaving, try to restate the working diagnosis, the goal of the plan, what you are expected to observe, and how unanswered questions will be revisited. If treatment is discussed, ask the prescribing clinician for the exact instructions and when and how to contact the care team. Evidence Evidence This statement has a dated source and is waiting for a clinician's sign-off. Pending clinical review
Why this item matters
- Reasonably supported
The vitiligo guidance I read treats assessment of activity, response, quality of life, and changing goals as parts of ongoing management. A plan is easier to follow when you understand what is being evaluated, rather than leaving with only the name of a treatment.
Check before moving on
- Depends on you
A clinician may not be able to predict the course or promise a particular result. “We do not know yet, and here is how we will reassess” can be a more useful plan than false certainty.
Questions for your clinician
What do we know now, and what is still uncertain?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What should make me call sooner?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How will we decide whether to continue or change the plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.